Healthcare provider profile · identity verified

James Nguyen, MD

Family Practice · NEW YORK, NY · NPI 1154363323

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	579	198
Amlodipine Besylate	Amlodipine Besylate	490	154
Metformin Hcl	Metformin Hcl	267	92
Albuterol Sulfate Hfa	Albuterol Sulfate	212	50
Lisinopril	Lisinopril	198	74
Hydrochlorothiazide	Hydrochlorothiazide	180	63
Losartan Potassium	Losartan Potassium	160	59
Omeprazole	Omeprazole	147	47
Levothyroxine Sodium	Levothyroxine Sodium	121	45
Rosuvastatin Calcium	Rosuvastatin Calcium	121	45
Metoprolol Succinate	Metoprolol Succinate	106	40
Alendronate Sodium	Alendronate Sodium	97	32
Fluticasone Propionate	Fluticasone Propionate	93	47
Tamsulosin Hcl	Tamsulosin Hcl	90	32
Simvastatin	Simvastatin	83	31
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	77	24
Trazodone Hcl	Trazodone Hcl	68	16
Montelukast Sodium	Montelukast Sodium	65	21
Triamcinolone Acetonide	Triamcinolone Acetonide	58	35
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	57	11
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	54	53
Ozempic	Semaglutide	53	13
Glipizide	Glipizide	50	16
Clopidogrel	Clopidogrel Bisulfate	49	17
Januvia	Sitagliptin Phosphate	49	14
Ibuprofen	Ibuprofen	47	23
Farxiga	Dapagliflozin Propanediol	39	12
Ezetimibe	Ezetimibe	38	13
Novolog Flexpen	Insulin Aspart	38	suppressed
Carvedilol	Carvedilol	35	13
Azithromycin	Azithromycin	32	29
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	21
Pravastatin Sodium	Pravastatin Sodium	32	11
Synthroid	Levothyroxine Sodium	32	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	31	suppressed
Eliquis	Apixaban	30	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	30	suppressed
Allopurinol	Allopurinol	29	suppressed
Famotidine	Famotidine	29	14
Finasteride	Finasteride	29	11
Gabapentin	Gabapentin	27	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	12
Naproxen	Naproxen	27	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	21
Chlorthalidone	Chlorthalidone	23	suppressed
Ketoconazole	Ketoconazole	23	suppressed
Jardiance	Empagliflozin	22	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	11
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	20	suppressed
Enalapril Maleate	Enalapril Maleate	20	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	18	suppressed
Single Use Swab	Alcohol Antiseptic Pads	18	suppressed
Atenolol	Atenolol	17	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Prednisone	Prednisone	16	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Sildenafil Citrate	Sildenafil Citrate	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Betamethasone Valerate	Betamethasone Valerate	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error